TY  - JOUR
AU  - Ayala Díaz, Rosa María
AU  - Carreño Tarragona, Gonzalo
AU  - Barragán, Eva
AU  - Boluda, Blanca
AU  - Larráyoz, María J.
AU  - Chillón, María Carmen
AU  - Carrillo Cruz, Estrella
AU  - Bilbao, Cristina
AU  - Sánchez García, Joaquín
AU  - Bernal, Teresa
AU  - Martínez Cuadrón, David
AU  - Gil, Cristina
AU  - Serrano, Josefina
AU  - Rodríguez Medina, Carlos
AU  - Bergua, Juan
AU  - Pérez Simón, José A.
AU  - Calbacho, María
AU  - Alonso Domínguez, Juan Manuel
AU  - Labrador, Jorge
AU  - Tormo, Mar
AU  - Amigo, Maria Luz
AU  - Herrera Puente, Pilar
AU  - Rapado, Inmaculada
AU  - Sargas, Claudia
AU  - Vázquez, Iria
AU  - Calasanz, María J.
AU  - Gómez Casares, Teresa
AU  - García Sanz, Ramón
AU  - Sanz, Miguel A.
AU  - Martínez López, Joaquín
AU  - Montesinos, Pau
PY  - 2022
DO  - 10.3390/cancers14235799
SN  - 2072-6694
UR  - https://hdl.handle.net/20.500.14352/72316
T2  - Cancers
AB  - FLT3–ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains...
LA  - eng
M2  - 5799
PB  - MDPI
KW  - FLT3–ITD mutation and ratio
KW  - Real-world outcomes
KW  - Acute myeloid leukemia (AML)
KW  - Prognosis
KW  - Outcome
KW  - Death
KW  - Relapse
KW  - Survival
TI  - Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
TY  - journal article
VL  - 14
ER  -